Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases. As an active player in the evolving medical robotic industry, these innovative solutions aim to make medical procedures safer thanks to reliable technologies, while complementing manual interventions.
R-One™ is the first solution developed by Robocath. It uses a unique technology that optimizes the safety of robotic-assisted coronary angioplasty. This medical procedure consists of revascularizing the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood. Every 30 seconds, somewhere in the world, this type of procedure is performed.
R-One™ is designed to operate with precision and perform specific movements, creating better interventional conditions. Thanks to its open architecture, R-One™ is compatible with
market-leading devices and cath labs.
In a prospective, randomized, controlled pre-clinical trial, R-One™ demonstrated safety and efficacy as it achieved 100% technical procedure success and no MACE (Major adverse cardiovascular events). R-One™ received the CE marking in February 2019 and started its clinical application in September 2019. Currently R-One™ is available in Europe and Africa.
Robocath aims to become the world leader in vascular robotics and develop the remote treatment of vascular emergencies, guaranteeing the best care pathway for all.
Based in Rouen, France, Robocath has more than 30 employees and is financially supported by regional investment funds (GO CAPITAL, NCI, Normandie Participations), national investment funds (M Capital, Supernova Invest), by several business angels and financial institutions (Caisse d'épargne, BNP Paribas, Crédit Agricole) and Bpifrance.